GSK: sotrovimab effective against Omicron variant
(CercleFinance.com) - GlaxoSmithKline and Vir Biotechnology today announced that preclinical data has demonstrated that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron variant of Covid.
To date, sotrovimab has demonstrated continued activity against all tested variants of concern and interest as defined by the World Health Organization (WHO), both companies said.
GlaxoSmithKline and Vir Biotechnology say they are currently conducting in vitro pseudovirus testing to confirm the neutralising activity of sotrovimab against the combination of all Omicron mutations, intending to provide an update by the end of 2021.
Copyright (c) 2021 CercleFinance.com. All rights reserved.